High-throughput single-cell screening of viable hybridomas and patient-derived antibody-secreting cells using punchable microwells

Monoclonal antibodies (mAbs) hold significant potential as therapeutic agents and are invaluable tools in biomedical research. However, the lack of efficient high-throughput screening methods for single antibody-secreting cells (ASCs) has limited the diversity of available antibodies. Here, we intro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Artificial cells, nanomedicine, and biotechnology nanomedicine, and biotechnology, 2024-12, Vol.52 (1), p.426-436
Hauptverfasser: Rubben, Kaat, Vander Plaetsen, Ann-Sophie, Almey, Ruben, Tytgat, Olivier, Deserranno, Koen, Debaere, Jamie, Acar, Delphine Diana, Meuleman, Philip, Deforce, Dieter, Van Nieuwerburgh, Filip
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Monoclonal antibodies (mAbs) hold significant potential as therapeutic agents and are invaluable tools in biomedical research. However, the lack of efficient high-throughput screening methods for single antibody-secreting cells (ASCs) has limited the diversity of available antibodies. Here, we introduce a novel, integrated workflow employing self-seeding microwells and an automated microscope-puncher system for the swift, high-throughput screening and isolation of single ASCs. The system allows for the individual screening and isolation of up to 6,400 cells within approximately one day, with the opportunity for parallelization and efficient upscaling. We successfully applied this workflow to both hybridomas and human patient-derived B cells, enabling subsequent clonal expansion or antibody sequence analysis through an optimized, single-cell nested reverse transcription-polymerase chain reaction (RT-PCR) procedure. By providing a time-efficient and more streamlined single ASC screening and isolation process, our workflow holds promise for driving forward progress in mAb development.
ISSN:2169-1401
2169-141X
2169-141X
DOI:10.1080/21691401.2024.2395815